Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6550307 | 0.92 | MGLL (0.50) | POLBCNR1PTGS1PTGS2MGLL | |
| SCHEMBL11446912 | 0.92 | MGLL (0.50) | POLBCNR1PTGS1PTGS2MGLL | |
| SCHEMBL11447070 | 0.89 | POLB (0.46) | SMN1; SMN2POLBMGLLFAAHRAB9A | |
| SCHEMBL11445778 | 0.87 | POLB (0.45) | SMN1; SMN2POLBCNR1PTGS1PTGS2 | |
| SCHEMBL11445763 | 0.87 | POLB (0.45) | SMN1; SMN2POLBCNR1PTGS1PTGS2 | |
| SCHEMBL8674736 | 0.84 | POLB (0.50) | SMN1; SMN2POLBGAAKMT2AALDH1A1 | |
| SCHEMBL5584328 | 0.82 | POLB (0.61) | SMN1; SMN2POLBCNR1RAB9AGAA | |
| SCHEMBL23733524 | 0.80 | PTGS1 (0.43) | SMN1; SMN2CNR1PTGS1PTGS2MGLL | |
| SCHEMBL11387429 | 0.79 | CNR1 (0.38) | SMN1; SMN2POLBCNR1PTGS1PTGS2 | |
| SCHEMBL14227264 | 0.78 | PTGS1 (0.38) | SMN1; SMN2CNR1PTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100181527-A1 | NITROXIDE CONTAINING ELECTRODE MATERIALS FOR SECONDARY BATTERIES | CIBA CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2162937-A1 | NITROXIDE CONTAINING ELECTRODE MATERIALS FOR SECONDARY BATTERIES | BASF SE (DE) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008155247-A1 | NITROXIDE CONTAINING ELECTRODE MATERIALS FOR SECONDARY BATTERIES | BASF SE (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100181527-A1 | NITROXIDE CONTAINING ELECTRODE MATERIALS FOR SECONDARY BATTERIES | CAT, NQO1, NUCB2 | SMN1; SMN2 1860/4885POLB 98/4885CNR1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.